Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Kindred Biosciences stock

KIN
US4945771099
A1XA6K

Price

0
Today +/-
-0
Today %
-0 %

Kindred Biosciences stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Kindred Biosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kindred Biosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kindred Biosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kindred Biosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kindred Biosciences Stock Price History

DateKindred Biosciences Price
8/27/20210 undefined
8/26/20210 undefined

Kindred Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Kindred Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kindred Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kindred Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kindred Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kindred Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kindred Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kindred Biosciences’s growth potential.

Kindred Biosciences Revenue, EBIT and net profit per share

DateKindred Biosciences RevenueKindred Biosciences EBITKindred Biosciences Net Income
2024e0 undefined0 undefined0 undefined
2023e0 undefined0 undefined0 undefined
2022e0 undefined0 undefined0 undefined
2021e0 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined

Kindred Biosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021e2022e2023e2024e
0000000000000
-------------
-------------
0000000000000
0000000000000
-------------
0000000000000
-------------
Details

Keystats

Revenue and Growth

The Kindred Biosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kindred Biosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020
                 
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
                 
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Kindred Biosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kindred Biosciences's financial health and stability.

Assets

Kindred Biosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kindred Biosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kindred Biosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kindred Biosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
000000000
---------
000000000
000000000
000000000
000000000

Kindred Biosciences stock margins

The Kindred Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kindred Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kindred Biosciences.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kindred Biosciences's sales revenue. A higher gross margin percentage indicates that the Kindred Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kindred Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kindred Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kindred Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kindred Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kindred Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kindred Biosciences Margin History

Kindred Biosciences Gross marginKindred Biosciences Profit marginKindred Biosciences EBIT marginKindred Biosciences Profit margin
2024e0 %0 %0 %
2023e0 %0 %0 %
2022e0 %0 %0 %
2021e0 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Kindred Biosciences Stock Sales Revenue, EBIT, Earnings per Share

The Kindred Biosciences earnings per share therefore indicates how much revenue Kindred Biosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Kindred Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kindred Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kindred Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kindred Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kindred Biosciences Revenue, EBIT and net profit per share

DateKindred Biosciences Sales per ShareKindred Biosciences EBIT per shareKindred Biosciences Earnings per Share
2024e0 undefined0 undefined0 undefined
2023e0 undefined0 undefined0 undefined
2022e0 undefined0 undefined0 undefined
2021e0 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined

Kindred Biosciences business model

Kindred Biosciences Inc. is a biopharmaceutical company that was founded in 2012 by Richard Chin, an experienced pharmaceutical entrepreneur. The company's goal is to develop and bring to market innovative animal medicines for pets. The business model of Kindred Biosciences is based on the identification and development of novel, safe, and effective animal medicines for dogs, cats, and horses. The company utilizes state-of-the-art technologies and research methods to develop high-quality products that meet the needs of veterinarians and pet owners. The company currently has three main business segments: biologics, biopharmaceuticals, and small molecules. Each of these segments focuses on specific animal diseases and offers a unique range of products. The biologics segment of Kindred Biosciences develops innovative vaccines for dogs and cats that are highly effective and have improved tolerability. Kindred Biosciences' vaccines are specifically tailored to the needs of pets and can help prevent infections and diseases in dogs and cats. The biopharmaceuticals segment of Kindred Biosciences develops novel therapies for chronic diseases in dogs and cats, such as chronic pain, inflammation, and cancer. The company utilizes state-of-the-art technologies and research methods to develop effective and safe therapies that meet the needs of veterinarians and pet owners. The small molecules segment of Kindred Biosciences develops novel drugs for horses that are highly effective and have improved tolerability. Kindred Biosciences' drugs are specifically tailored to the needs of horses and can help treat various conditions such as arthritis or colic. The company has a broad range of products, currently consisting of over a dozen products that focus on different animal species, diseases, and needs. These include therapies for chronic pain, inhalation anesthetics, drugs for cancer and inflammation, as well as vaccines for various infections. Kindred Biosciences has achieved significant success in recent years. The company has conducted numerous clinical trials and brought several drugs and vaccines to market. In 2018, the company received approval from the Food and Drug Administration (FDA) for a groundbreaking therapy for chronic pain in dogs. The company also has a strong pipeline of products in development that could contribute to supporting the company's growth in the coming years. In summary, Kindred Biosciences is an innovative biopharmaceutical company focused on the development and commercialization of innovative animal medicines. The company has a broad range of products and is capable of developing high-quality products for a variety of animal species, diseases, and needs. With a strong pipeline and a successful track record, Kindred Biosciences is well-positioned to solidify its leading position in the industry and accelerate its growth in the coming years. Kindred Biosciences is one of the most popular companies on Eulerpool.com.

Kindred Biosciences SWOT Analysis

Strengths

Kindred Biosciences Inc has a strong portfolio of innovative animal healthcare products, which positions the company as a market leader in the industry. The company's extensive research and development efforts have resulted in successful formulations and treatments for a wide range of animal diseases.

Kindred Biosciences Inc's strong distribution network allows for efficient and widespread availability of its products. The company has established partnerships with various veterinary clinics, pharmacies, and distributors, ensuring a broad reach and access to its target market.

Weaknesses

One notable weakness for Kindred Biosciences Inc is its relatively small size compared to some of its competitors. As a smaller company, it may face challenges in terms of resources and funding for research and development, as well as marketing and advertising efforts. This could limit its ability to compete at the same level as larger players in the industry.

Another weakness is the potential dependence on a limited number of key partners for distribution. If the company were to encounter any issues or disputes with these partners, it could have a negative impact on its distribution capabilities and market reach.

Opportunities

The increasing trend of pet ownership and the growing awareness about animal health present significant opportunities for Kindred Biosciences Inc. The company can capitalize on this by introducing new and improved products to cater to the evolving needs of pet owners and veterinarians.

Kindred Biosciences Inc can also explore expansion into international markets, leveraging its successful product portfolio and expertise in animal healthcare. This would allow the company to tap into new customer segments and drive additional revenue growth.

Threats

The animal healthcare industry is highly competitive, with the presence of numerous established players. Kindred Biosciences Inc faces the threat of intense competition and the possibility of larger competitors dominating the market, potentially limiting its market share and profitability.

Legislative changes and regulations related to animal health and pharmaceuticals can also pose threats to the company's operations. Compliance with these regulations and potential changes in regulatory requirements may result in additional costs and challenges for Kindred Biosciences Inc.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Kindred Biosciences Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kindred Biosciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Kindred Biosciences shares outstanding

The number of shares was Kindred Biosciences in 2023 — This indicates how many shares 39.29 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Kindred Biosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kindred Biosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kindred Biosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kindred Biosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Kindred Biosciences.

Kindred Biosciences shareholders

%
Name
Stocks
Change
Date
15.06007 % Elanco Animal Health, Inc6,846,6576,846,6577/20/2021
13.19775 % Park West Asset Management LLC6,000,002-414,9837/20/2021
8.46899 % Point72 Asset Management, L.P.3,850,2003,850,2003/31/2021
7.52585 % Magnetar Capital Partners LP3,421,4253,421,4256/28/2021
5.67437 % Millennium Management LLC2,579,6982,556,5766/23/2021
5.42957 % BlackRock Institutional Trust Company, N.A.2,468,40765,6593/31/2021
4.40556 % The Vanguard Group, Inc.2,002,87019,8453/31/2021
4.19028 % Columbia Threadneedle Investments (UK)1,904,99823,3043/31/2021
4.18428 % Chin (Richard H)1,902,271-40,0007/20/2021
3.11656 % Renaissance Technologies LLC1,416,859-173,0003/31/2021
1
2
3
4
5
...
10

Most common questions regarding Kindred Biosciences

What values and corporate philosophy does Kindred Biosciences represent?

Kindred Biosciences Inc represents a strong commitment to improving the lives of animals through innovative veterinary biologics and therapeutics. The company values include integrity, innovation, collaboration, and a dedication to scientific excellence. Kindred Biosciences is driven by a corporate philosophy that emphasizes the importance of research and development, aiming to address unmet veterinary needs and provide effective treatments for various animal species. By leveraging cutting-edge technologies and partnerships, Kindred Biosciences strives to make a positive impact on animal health, while also creating value for its shareholders.

In which countries and regions is Kindred Biosciences primarily present?

Kindred Biosciences Inc primarily operates in the United States.

What significant milestones has the company Kindred Biosciences achieved?

Since its establishment, Kindred Biosciences Inc has accomplished several significant milestones. The company successfully received approval from the Food and Drug Administration (FDA) for their groundbreaking therapies, such as Zimeta, Mirataz, and KIND-016. Additionally, Kindred Biosciences Inc has entered into strategic partnerships and collaborations with renowned pharmaceutical companies, enabling them to expand their research and development capabilities. These partnerships have played a pivotal role in advancing the company's pipeline, leading to the development of innovative treatments for various animal diseases. Kindred Biosciences Inc continues to exhibit strong commitment towards improving animal health and welfare through their pioneering achievements and ongoing efforts.

What is the history and background of the company Kindred Biosciences?

Kindred Biosciences Inc, a biopharmaceutical company, has a fascinating history and background. It was founded in 2012 and is headquartered in California, United States. The company specializes in developing innovative medicines for veterinary use. Kindred Biosciences is committed to enhancing the lives of pets by focusing on unmet medical needs. With a highly experienced team and state-of-the-art facilities, they strive to develop effective therapies and treatments for various animal diseases. Kindred Biosciences has gained recognition for its dedication to animal health and its successful development of novel biologics. Continuously expanding its product portfolio, the company seeks to revolutionize veterinary medicine.

Who are the main competitors of Kindred Biosciences in the market?

The main competitors of Kindred Biosciences Inc in the market are Zoetis Inc., Elanco Animal Health Inc., and IDEXX Laboratories Inc.

In which industries is Kindred Biosciences primarily active?

Kindred Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Kindred Biosciences?

The business model of Kindred Biosciences Inc, a biopharmaceutical company, focuses on veterinary medicine. They develop innovative therapeutics for animals, aiming to improve the lives of pets and horses. Kindred Biosciences creates drugs for various conditions that affect animals, including allergies, infections, and gastrointestinal disorders. Their mission is to provide effective and safe medications to improve the well-being of companion animals. With a strong commitment to research and development, Kindred Biosciences pioneers advancements in animal healthcare, seeking to address unmet medical needs in the veterinary industry and contribute to the overall betterment of animal health.

What is the P/E ratio of Kindred Biosciences 2024?

The P/E ratio cannot be calculated for Kindred Biosciences at the moment.

What is the P/S ratio of Kindred Biosciences 2024?

The P/S cannot be calculated for Kindred Biosciences currently.

What is the Quality Investing of Kindred Biosciences?

The Quality Investing for Kindred Biosciences is 1/10.

What is the revenue of Kindred Biosciences 2024?

The revenue cannot currently be calculated for Kindred Biosciences.

How high is the profit of Kindred Biosciences 2024?

The profit cannot currently be calculated for Kindred Biosciences.

What is the business model of Kindred Biosciences

Kindred Biosciences Inc. is a biopharmaceutical company focused on the development of innovative animal health products. The company aims to improve animal lives and provide pet owners with innovative and effective therapies. It is divided into three main business areas: Biologics, small molecules, and diagnostics. In the field of Biologics, Kindred Biosciences develops innovative biopharmaceutical products for animals. The focus is on researching and developing antibodies and proteins that block or neutralize disease-causing target molecules. Examples include Zimeta, an injectable medication for treating fever in horses, and KIND-010, an antibody for treating atopic dermatitis in dogs. The small molecules division focuses on developing chemical compounds for treating diseases in animals. Kindred Biosciences uses its own technology platform to identify and optimize molecules that bind to specific target molecules in the body. An example is Mirataz, a topical gel for treating cats with compulsive disorders. The diagnostics division offers a wide range of tests and instruments for the rapid and reliable diagnosis of animal diseases. For example, the SUCCEED Equine Fecal Blood Test measures the worm burden in horses, allowing for targeted deworming. Kindred Biosciences also conducts extensive research and development to continuously expand and improve its portfolio of animal health products. The company collaborates closely with the veterinary community and utilizes advanced technologies and methods such as protein engineering and CRISPR/Cas9 to explore new therapeutic approaches. Overall, Kindred Biosciences offers a broad range of animal health products valued by both veterinarians and pet owners. The company stands out for its strong research and development efforts, close collaboration with the veterinary community, and innovative technologies. With a strong market position and solid growth strategy, Kindred Biosciences is an important player in the animal health products market.

What is the Kindred Biosciences dividend?

Kindred Biosciences pays a dividend of 0 USD distributed over payouts per year.

How often does Kindred Biosciences pay dividends?

The dividend cannot currently be calculated for Kindred Biosciences or the company does not pay out a dividend.

What is the Kindred Biosciences ISIN?

The ISIN of Kindred Biosciences is US4945771099.

What is the Kindred Biosciences WKN?

The WKN of Kindred Biosciences is A1XA6K.

What is the Kindred Biosciences ticker?

The ticker of Kindred Biosciences is KIN.

How much dividend does Kindred Biosciences pay?

Over the past 12 months, Kindred Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kindred Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kindred Biosciences?

The current dividend yield of Kindred Biosciences is .

When does Kindred Biosciences pay dividends?

Kindred Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kindred Biosciences?

Kindred Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kindred Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kindred Biosciences located?

Kindred Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kindred Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kindred Biosciences from 12/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/5/2024.

When did Kindred Biosciences pay the last dividend?

The last dividend was paid out on 12/5/2024.

What was the dividend of Kindred Biosciences in the year 2023?

In the year 2023, Kindred Biosciences distributed 0 USD as dividends.

In which currency does Kindred Biosciences pay out the dividend?

The dividends of Kindred Biosciences are distributed in USD.

All fundamentals about Kindred Biosciences

Our stock analysis for Kindred Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kindred Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.